<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912661</url>
  </required_header>
  <id_info>
    <org_study_id>DIVA I</org_study_id>
    <nct_id>NCT04912661</nct_id>
  </id_info>
  <brief_title>Iron and Vaccine Response</brief_title>
  <official_title>Iron and Vaccine-preventable Viral Disease - an Experimental Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jomo Kenyatta University of Agriculture and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Federal Institute of Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccines often underperform in Africa compared to high-income countries. Why vaccines do not&#xD;
      work as well in Africa remains uncertain. Malnutrition likely plays a role. Our study&#xD;
      objective is to assess whether iron deficiency anaemia in young women impairs their immune&#xD;
      response to viral vaccines, and whether iron treatment improves their response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group 1 (immediate iron treatment) will receive iron treatment before vaccination. Women in&#xD;
      both groups will receive two intramuscular vaccines (influenza and yellow fever). Vaccine&#xD;
      response will be measured 28 and 56 days after vaccine administration in both groups. Group 2&#xD;
      (delayed iron treatment) will receive iron treatment at study end.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2021</start_date>
  <completion_date type="Actual">September 9, 2021</completion_date>
  <primary_completion_date type="Actual">September 9, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>at 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>at 63 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>at 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>at 63 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody avidity Index</measure>
    <time_frame>at 35 days</time_frame>
    <description>percentage of antibodies that remain bound to beads</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody avidity Index</measure>
    <time_frame>at 63 days</time_frame>
    <description>percentage of antibodies that remain bound to beads</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>antiviral immunoglobulin G response</measure>
    <time_frame>day 0</time_frame>
    <description>Immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antiviral immunoglobulin G response</measure>
    <time_frame>day 7</time_frame>
    <description>Immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antiviral immunoglobulin G response</measure>
    <time_frame>day 35</time_frame>
    <description>Immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antiviral immunoglobulin G response</measure>
    <time_frame>day 63</time_frame>
    <description>Immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune cell populations</measure>
    <time_frame>day 0</time_frame>
    <description>number and type of immune cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune cell populations</measure>
    <time_frame>day 7</time_frame>
    <description>number and type of immune cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune cell populations</measure>
    <time_frame>day 35</time_frame>
    <description>number and type of immune cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune cell populations</measure>
    <time_frame>day 63</time_frame>
    <description>number and type of immune cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics</measure>
    <time_frame>day 0</time_frame>
    <description>Proteins involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics</measure>
    <time_frame>day 7</time_frame>
    <description>Proteins involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics</measure>
    <time_frame>day 35</time_frame>
    <description>Proteins involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics</measure>
    <time_frame>day 63</time_frame>
    <description>Proteins involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomics</measure>
    <time_frame>day 0</time_frame>
    <description>Genes involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomics</measure>
    <time_frame>day 7</time_frame>
    <description>Genes involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomics</measure>
    <time_frame>day 35</time_frame>
    <description>Genes involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomics</measure>
    <time_frame>day 63</time_frame>
    <description>Genes involved in immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell cytokine secretion</measure>
    <time_frame>day 7</time_frame>
    <description>ELISpot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell cytokine secretion</measure>
    <time_frame>day 35</time_frame>
    <description>ELISpot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>day 0</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>day 7</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>day 35</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>day 63</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Ferritin</measure>
    <time_frame>day 0</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Ferritin</measure>
    <time_frame>day 7</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Ferritin</measure>
    <time_frame>day 35</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Ferritin</measure>
    <time_frame>day 63</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin receptor</measure>
    <time_frame>day 0</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin receptor</measure>
    <time_frame>day 7</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin receptor</measure>
    <time_frame>day 35</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin receptor</measure>
    <time_frame>day 63</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation</measure>
    <time_frame>day 0</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation</measure>
    <time_frame>day 7</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation</measure>
    <time_frame>day 35</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation</measure>
    <time_frame>day 63</time_frame>
    <description>iron status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>day 0</time_frame>
    <description>inflammation status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>day 7</time_frame>
    <description>inflammation status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>day 35</time_frame>
    <description>inflammation status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>day 63</time_frame>
    <description>inflammation status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-glycoprotein</measure>
    <time_frame>day 0</time_frame>
    <description>inflammation status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-glycoprotein</measure>
    <time_frame>day 7</time_frame>
    <description>inflammation status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-glycoprotein</measure>
    <time_frame>day 28</time_frame>
    <description>inflammation status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-glycoprotein</measure>
    <time_frame>day 56</time_frame>
    <description>inflammation status parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>retinol binding protein</measure>
    <time_frame>day 0</time_frame>
    <description>marker for Vitamin A status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>retinol binding protein</measure>
    <time_frame>day 7</time_frame>
    <description>marker for Vitamin A status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>retinol binding protein</measure>
    <time_frame>day 35</time_frame>
    <description>marker for Vitamin A status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>retinol binding protein</measure>
    <time_frame>day 63</time_frame>
    <description>marker for Vitamin A status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma zinc</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma zinc</measure>
    <time_frame>day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma zinc</measure>
    <time_frame>day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma zinc</measure>
    <time_frame>day 63</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <condition>Vaccine Preventable Disease</condition>
  <condition>Vaccine Response Impaired</condition>
  <condition>Iron Deficiency Anemia Treatment</condition>
  <arm_group>
    <arm_group_label>Immediate iron treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous iron carboxymaltose before vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No iron treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intravenous iron carboxymaltose before vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ferinject</intervention_name>
    <description>intravenous iron carboxymaltose</description>
    <arm_group_label>Immediate iron treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-55 years old&#xD;
&#xD;
          -  Zinc protoporphyrin &gt; or equal 40 mmol/mol heme&#xD;
&#xD;
          -  hemoglobin &lt; or equal 109 g/L&#xD;
&#xD;
          -  no malaria&#xD;
&#xD;
          -  no known HIV infection&#xD;
&#xD;
          -  no medical condition that precludes study involvement&#xD;
&#xD;
          -  no iron supplementation 1 week prior to study start&#xD;
&#xD;
          -  no recent tuberculosis infection&#xD;
&#xD;
          -  no vaccination of yellow fever or influenza prior to enrolment&#xD;
&#xD;
          -  not pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Stoffel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ETH Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Msambweni County Referral Hospital</name>
      <address>
        <city>Msambweni</city>
        <state>Kwale</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Federal Institute of Technology</investigator_affiliation>
    <investigator_full_name>Nicole Stoffel</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccine-Preventable Diseases</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

